Vaccines (Aug 2024)

DNA Vaccines Encoding HTNV GP-Derived Th Epitopes Benefited from a LAMP-Targeting Strategy and Established Cellular Immunoprotection

  • Dongbo Jiang,
  • Junqi Zhang,
  • Wenyang Shen,
  • Yubo Sun,
  • Zhenjie Wang,
  • Jiawei Wang,
  • Jinpeng Zhang,
  • Guanwen Zhang,
  • Gefei Zhang,
  • Yueyue Wang,
  • Sirui Cai,
  • Jiaxing Zhang,
  • Yongkai Wang,
  • Ruibo Liu,
  • Tianyuan Bai,
  • Yuanjie Sun,
  • Shuya Yang,
  • Zilu Ma,
  • Zhikui Li,
  • Jijin Li,
  • Chenjin Ma,
  • Linfeng Cheng,
  • Baozeng Sun,
  • Kun Yang

DOI
https://doi.org/10.3390/vaccines12080928
Journal volume & issue
Vol. 12, no. 8
p. 928

Abstract

Read online

Vaccines has long been the focus of antiviral immunotherapy research. Viral epitopes are thought to be useful biomarkers for immunotherapy (both antibody-based and cellular). In this study, we designed a novel vaccine molecule, the Hantaan virus (HTNV) glycoprotein (GP) tandem Th epitope molecule (named the Gnc molecule), in silico. Subsequently, computer analysis was used to conduct a comprehensive and in-depth study of the various properties of the molecule and its effects as a vaccine molecule in the body. The Gnc molecule was designed for DNA vaccines and optimized with a lysosomal-targeting membrane protein (LAMP) strategy. The effects of GP-derived Th epitopes and multiepitope vaccines were initially verified in animals. Our research has resulted in the design of two vaccines based on effective antiviral immune targets. The effectiveness of molecular therapies has also been preliminarily demonstrated in silico and in laboratory animals, which lays a foundation for the application of a vaccines strategy in the field of antivirals.

Keywords